KRAS and cancer: In addition, some cancer types, such as RB1-deficient breast cancers, KRAS-driven cancers, and chemoresistant melanoma, are particularly reliant on OXPHOS activity and are especially sensitive to OXPHOS inhibition [54,55,56].